stockrow
Saturday 7 November 2026
Export MGTX’s income statement to Excel — free account
MeiraGTx Holdings PLC
MGTX Healthcare Biotechnology
MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024.
- Revenue
- +8,608.6%
- EPS
- +466.7%
- Free cash flow
- +13.1%
- Total debt
- +28.6%
Quarter to June 2026, against a year earlier
8.99
0.48
+5.64%
Follow MGTX
Alert me
MeiraGTx Holdings PLC (MGTX) P/E ratio
As of 6 November 2026, MeiraGTx Holdings PLC (MGTX) trades at a P/E ratio of 11.8×. Over the past ten years it has ranged from 0.0× (June 2026) to 19.7× (August 2026); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 17.8× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 26 more quarters | Free account |
Against its own ten years
Low 0.0×
High 19.7×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| ALMS Alumis Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.4× |
| MGTX MeiraGTx Holdings PLC | 11.8× |
| LTGO Latigo Biotherapeutics Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)